Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW.

Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3.

2.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049
3.

Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.

Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, Anagnostopoulos C, Cournia Z, Tamvakopoulos C, Klinakis A, Efstratiadis A.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju320. doi: 10.1093/jnci/dju320. Print 2014 Dec.

4.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

5.

Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.

Hu G, Li F, Ouyang K, Xie F, Tang X, Wang K, Han S, Jiang Z, Zhu M, Wen D, Qin X, Zhang L.

Int J Oncol. 2012 Mar;40(3):798-806. doi: 10.3892/ijo.2011.1254. Epub 2011 Nov 7.

PMID:
22076649
6.

K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.

Wei F, Liu Y, Bellail AC, Olson JJ, Sun SY, Lu G, Ding L, Yuan C, Wang G, Hao C.

Cancer Lett. 2012 Sep 1;322(1):58-69. doi: 10.1016/j.canlet.2012.02.005. Epub 2012 Feb 14.

7.

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, Nostro C, Wang R, Muthuswamy LB, Crawford HC, Arrowsmith C, Kalloger SE, Renouf DJ, Connor AA, Cleary S, Schaeffer DF, Roehrl M, Tsao MS, Gallinger S, Keller G, Muthuswamy SK.

Nat Med. 2015 Nov;21(11):1364-71. doi: 10.1038/nm.3973. Epub 2015 Oct 26.

8.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.

Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8.

9.

New biomarkers and targets in pancreatic cancer and their application to treatment.

Costello E, Greenhalf W, Neoptolemos JP.

Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):435-44. doi: 10.1038/nrgastro.2012.119. Epub 2012 Jun 26. Review.

PMID:
22733351
10.

Mutant KRAS is a druggable target for pancreatic cancer.

Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2.

11.

New developments in pancreatic cancer treatment.

Krug S, Michl P.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):427-43. Review.

PMID:
23207616
12.

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.

Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26.

13.

Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition.

Appari M, Babu KR, Kaczorowski A, Gross W, Herr I.

Int J Oncol. 2014 Oct;45(4):1391-400. doi: 10.3892/ijo.2014.2539. Epub 2014 Jul 8.

14.

N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer.

Su Y, Li J, Witkiewicz AK, Brennan D, Neill T, Talarico J, Radice GL.

Oncogene. 2012 Oct 11;31(41):4484-9. doi: 10.1038/onc.2011.574. Epub 2011 Dec 12.

15.

Use of predictive markers in oncology: are phase 3 trials always required?

Markman M.

Oncology. 2011;81(1):1-2. doi: 10.1159/000330729. Epub 2011 Sep 2. No abstract available.

16.

miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.

Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.

Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.

PMID:
23440261
17.

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M.

Cancer Cell. 2012 Sep 11;22(3):318-30. doi: 10.1016/j.ccr.2012.08.001.

18.

Stromal biology and therapy in pancreatic cancer.

Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA.

Gut. 2011 Jun;60(6):861-8. doi: 10.1136/gut.2010.226092. Epub 2010 Oct 21. Review.

PMID:
20966025
19.

A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.

Wang H, Pei W, Luan Q, Ma F, Zhou S, Zhao Z, Meng X, Zhang X, Liang X, Chen Y, Zhan Q, Lin C, Qian H, Zhao P.

Cancer Biol Ther. 2012 Jul;13(9):712-9. Epub 2012 May 23.

PMID:
22617775
20.

Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Pérez-Torras S, Vidal-Pla A, Miquel R, Almendro V, Fernández-Cruz L, Navarro S, Maurel J, Carbó N, Gascón P, Mazo A.

Cell Oncol (Dordr). 2011 Dec;34(6):511-21. doi: 10.1007/s13402-011-0049-1. Epub 2011 Jun 17.

PMID:
21681527
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk